

IL-23/IL-12/p40 ELISA
mAbs coated onto plates, cytokines used at 100 ng/ml
IL-23
p40
IL-12
OD
3
2
1
0
Anti-IL-12/23p40
C1273
C1275
C1269
C1249
20C2
PBS

Figure 1



3.0
2.5
2.0
1.5
1.5
1.0
0.5
0.0
OD
10^{-2}
10^{-1}
10^{0}
10^{1}
10^{2}
bt.IL-23, ng/ml
C1273
C1275
C1269
C1249

Figure 2



IL-23R-Fc
C1249
C1269
0.75
0.50
0.25
0.00
OD
0.001
0.01
0.1
1
10
100
mAb, ug/ml

Figure 3A



C1273
Neg. mAb
C1275
IL-23 no mAbs
1.00
0.75
0.50
0.25
0.00
OD
0.001
0.01
0.1
1
10
100
Ab ug/ml

Figure 3B



Anti-IL-12/23p40
No IL-23
Neg mAb
IL-23 no mAb
C1249
C1269
C1273
C1275
mIL-17, pg/ml
1100
1000
900
800
700
600
500
400
300
200
100
0
10-4
10-3
10-2
10-1
100
101
102
mAb ug/ml

Figure 4



hIL-23p19 (3220) Mutant
hIL-23
Relative %
120
100
80
60
40
20
0
CNTO 4088(1249)
CNTO 856 (1269)
CNTO 209
anti-Human IL-23p19 and anti-Mouse IL-23p19 mAb

Figure 5



G86
L109
K83
L110
E82
Helix C
S113
Q114
I79
L116
Q117
H75
Helix A
2
1

Figure 6



CNTO 856 (C1269)
CNTO 4088 (C1249)
Relative binding (%)
140
120
100
80
60
40
20
0
1
10
100
1000
10000
Competitor (nM)

Figure 7




Figure 8A




Figure 8B



120
100
80
60
40
20
0
Relative %
CNTO 4088
CNTO 856
CNTO 209
mIL-23
hIL-23
hIL23p19 Mutant (3220)
hIL23p19 Mutant (3397)

Figure 9